EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy

Bruno Silva-Santos iD, Sofia Mensurado iD, Rafael Blanco-Domínguez iD, Adrian C Hayday iD

Journal of Experimental Medicine · 2026

DOI: 10.1084/jem.20252289 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Bruno Silva-Santos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gulbenkian Institute for Molecular Medicine , Lisbon, Portugal. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Receptors, Antigen, T-Cell, gamma-delta, T-Lymphocyte Subsets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Molecular Biology Organisation, Ministério da Ciência, Tecnologia e Ensino Superior, Fundação para a Ciência e Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has mostly relied on conventional T cells to achieve success in a limited set of tumor types. A promising avenue to expand the repertoire of cancers effectively treated through immune intervention is to mobilize other anti-tumor effectors, such as γδ T cells. Among these, the Vδ1+ subset commonly predominates within peripheral tissues and within tumors, typically associating with good prognosis. In this Found in Translation, we discuss how to leverage the biological properties of Vδ1+ γδ T cells for cancer immunotherapy, with special focus on the delta one T (DOT) cell approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyReceptors, Antigen, T-Cell, gamma-deltaT-Lymphocyte SubsetsT-LymphocytesHumansAnimals

Substanzen

Receptors, Antigen, T-Cell, gamma-delta

Autor:innen und Institutionen

  • Gulbenkian Institute for Molecular Medicine , Lisbon, Portugal.
  • Faculdade de Medicina da Universidade de Lisboa , Lisbon, Portugal.
  • King's College London , London, UK.
  • The Francis Crick Institute , London, UK.

ORCID-Profile: Bruno Silva-Santos, Sofia Mensurado, Rafael Blanco-Domínguez, Adrian C Hayday

Förderung

  • European Molecular Biology Organisation
  • Ministério da Ciência, Tecnologia e Ensino Superior
  • Fundação para a Ciência e Tecnologia
  • Wellcome Trust
  • Takeda Development Center Americas

Zitieren

APA

Silva-Santos, B., Mensurado, S., Blanco-Domínguez, R., & Hayday, A. C. (2026). Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252289

Vancouver

Silva-Santos B, Mensurado S, Blanco-Domínguez R, Hayday AC. Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20252289

BibTeX
@article{SilvaSantos2026,
  author = {Silva-Santos, Bruno and Mensurado, Sofia and Blanco-Domínguez, Rafael and Hayday, Adrian C},
  title = {Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  doi = {10.1084/jem.20252289}
}
Kostenlos starten →